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ORIGINAL ARTICLE
FOXA1 repression is associated with loss of BRCA1 and
increased promoter methylation and chromatin silencing in
breast cancer
C Gong1,2,6, K Fujino1,3,6, LJ Monteiro1, AR Gomes1, R Drost4, H Davidson-Smith5, S Takeda3, US Khoo2, J Jonkers4,
D Sproul5 and EW-F Lam1
FOXA1 expression correlates with the breast cancer luminal subtype and patient survival. RNA and protein analysis of a panel of
breast cancer cell lines revealed that BRCA1 deﬁciency is associated with the downregulation of FOXA1 expression. Knockdown of
BRCA1 resulted in the downregulation of FOXA1 expression and enhancement of FOXA1 promoter methylation in MCF-7 breast
cancer cells, whereas the reconstitution of BRCA1 in Brca1-deﬁcent mouse mammary epithelial cells (MMECs) promoted Foxa1
expression and methylation. These data suggest that BRCA1 suppresses FOXA1 hypermethylation and silencing. Consistently, the
treatment of MMECs with the DNA methylation inhibitor 5-aza-2′-deoxycitydine induced Foxa1 mRNA expression. Furthermore,
treatment with GSK126, an inhibitor of EZH2 methyltransferase activity, induced FOXA1 expression in BRCA1-deﬁcient but not in
BRCA1-reconstituted MMECs. Likewise, the depletion of EZH2 by small interfering RNA enhanced FOXA1 mRNA expression.
Chromatin immunoprecipitation (ChIP) analysis demonstrated that BRCA1, EZH2, DNA methyltransferases (DNMT)1/3a/3b and
H3K27me3 are recruited to the endogenous FOXA1 promoter, further supporting the hypothesis that these proteins interact to
modulate FOXA1 methylation and repression. Further co-immunoprecipitation and ChIP analysis showed that both BRCA1 and
DNMT3b form complexes with EZH2 but not with each other, consistent with the notion that BRCA1 binds to EZH2 and negatively
regulates its methyltransferase activity. We also found that EZH2 promotes and BRCA1 impairs the deposit of the gene silencing
histone mark H3K27me3 on the FOXA1 promoter. These associations were validated in a familial breast cancer patient cohort.
Integrated analysis of the global gene methylation and expression proﬁles of a set of 33 familial breast tumours revealed that
FOXA1 promoter methylation is inversely correlated with the transcriptional expression of FOXA1 and that BRCA1 mutation breast
cancer is signiﬁcantly associated with FOXA1 methylation and downregulation of FOXA1 expression, providing physiological
evidence to our ﬁndings that FOXA1 expression is regulated by methylation and chromatin silencing and that BRCA1 maintains
FOXA1 expression through suppressing FOXA1 gene methylation in breast cancer.
Oncogene advance online publication, 22 December 2014; doi:10.1038/onc.2014.421
INTRODUCTION
Breast cancer is the most common female malignancies world-
wide, affecting one in nine women during their lifetime.
Hereditary breast cancer constitutes 5–10% of all breast cancer
cases. Together BRCA1 and BRCA2 mutations account for about
20–25% of all inherited breast cancers, and BRCA1/2-mutation
carriers face a high risk of developing breast cancer. BRCA1 has
diverse roles in breast cancer development and its multifaceted
functions include DNA damage repair, cell cycle checkpoint
control, protein ubiquitination and transcriptional control through
chromatin modiﬁcation and direct interaction with RNA polymer-
ase II holoenzyme complex.1 The vast majority of BRCA1-deﬁcient
tumours exhibit basal-like breast cancer phenotypes, which
include triple-negative receptor status (ER-, PR- and HER2-
negative), strong expression of basal cytokeratins, high p53
mutation rates and poor prognosis.2 Consistently, the loss of
BRCA1 hinders differentiation into ER-positive luminal cells,
leading to increased stem/progenitor cell-like self-renewal
properties.3,4 Nevertheless, the exact mechanism by which BRCA1
regulates the differentiation of luminal breast cancer cells is still
poorly understood. It has been suggested that BRCA1 might
regulate luminal differentiation through the transcriptional
activation of ER.5 BRCA1 might also regulate mammary cell fate
through transcriptional activation of Notch signalling pathway.2 In
addition, BRCA1 could also interact with GATA3 at its C-terminal
region to repress triple-negative and basal-like breast cancer
(BLBCs) associated genes, such as FOXC1.6
FOXA1 is a ‘pioneer’ forkhead transcription factor that can
directly bind condensed chromatin, displace repressive linker
histones and recruit other transcription factors to promote
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transcription.7,8 It is required by ERα as a cofactor for chromatin
binding9 and has been reported to regulate nearly 50% of all
oestrogen receptor (ER)-target genes.10 Thus, FOXA1 and ERα
constitute a major proliferative and survival axis for breast cancers,
speciﬁcally of the luminal A subtype. Crucially, FOXA1 is a
favourable prognostic marker10–12 and can directly repress the
expression of a subset of basal speciﬁc genes. Accordingly, the
silencing of FOXA1 causes a partial transcriptome shift from
luminal to basal gene expression signatures.13 FOXA1 may also
prevent metastatic progression of luminal subtype breast cancers
by controlling differentiation through enhancing the expression of
the negative cell cycle regulator p27Kip1 and the cell adhesion
molecule E-cadherin.14
EZH2 (enhancer of zeste homologue 2) is a subunit of the
polycomb-repressive complex 2 (PRC2) and its overexpression is
also associated with the presence of metastasis and poor survival
in breast cancer patients. EZH2 mediates the trimethylation of
histone 3 lysine 27 (H3K27me3), which serves as an epigenetic
code for subsequent recruitment of PRC1, DNA methyltransferases
(DNMTs) and histone deacetylases, resulting in chromatin
condensation and transcription suppression.15 In addition, EZH2
can also directly interact with DNMTs and regulate the methyla-
tion of EZH2-target genes,16 although these interactions might be
cell-type speciﬁc.17 Recently, EZH2 has also been functionally
linked with BRCA1 in breast cancer. It has been shown that the
growth of BRCA1-deﬁcient mouse mammary tumours is depen-
dant on EZH2 expression.18 Conversely, EZH2 inhibition in breast
cancer cell lines can cause BRCA1 nuclear exportation and
inactivation.19 Crucially, BRCA1 interacts directly with EZH2 in
both mouse embryonic stem cells and human breast cancer cells,
functioning as a negative modulator of EZH2 activity.20
In this study, we hypothesized that BRCA1 regulates FOXA1
expression and conﬁrmed it by the reconstitution or knockdown
of BRCA1. We found that BRCA1 deﬁciency correlates with the
repression of FOXA1 expression in mammary epithelial cancer cell
lines and that BRCA1 mutation is signiﬁcantly associated with
FOXA1 promoter methylation and silencing in human breast
tumours. We also went on to explore the potential molecular
mechanism involved and identiﬁed FOXA1 as an EZH2-regulated
gene in breast cancer cells.
RESULTS
Correlation between BRCA1 and FOXA1 expression in breast
cancer cell lines
The majority of BRCA1 mutation breast cancers are of the basal
subtype. The molecular phenotype of basal breast cancers has
been shown to be repressed by FOXA1 expression, which is
associated with the luminal phenotype.13 These ﬁndings raise the
possibility that BRCA1 and FOXA1 interact at the molecular level to
modulate the development of basal and luminal breast cancer
subtypes. To investigate the relationship between BRCA1 and
FOXA1, western blot analysis was performed on a panel of six
breast cancer cell lines, which include the luminal-type MCF-7 cells
with wild-type BRCA1 and the basal-type lines HCC70, MDA-
MB-231, MDA-MB-436, SUM1315MO2 and MDA-MB-468 expres-
sing either low or mutated BRCA121 (Figure 1a). Despite the great
heterogeneity among the cell lines, there was a good correlation
between the expression of wild-type BRCA1 and FOXA1. Similar
correlations between BRCA1 and FOXA1 expression were
observed in a panel of breast cancer cell lines with different
levels of wild-type BRCA1 (Supplementary Figure S1). In the basal-
type cell lines, FOXA1 expression was much lower when compared
with that of MCF-7, which supports the notion that FOXA1 is a
marker for luminal subtype breast cancer.13 The expression of
FOXA1 in MCF-7 cells was also signiﬁcantly higher compared with
the basal-type cell lines at the mRNA level (Figure 1b). Consistent
with this, other luminal markers, ERα and GATA3, were also only
expressed in considerable levels in MCF-7 cells. We also studied
the expression of the Polycomb protein EZH2, which has
previously been demonstrated to interact with BRCA120 and
found it ubiquitously expressed in all six cell lines. Notably, high
BRCA1 mRNA levels, which encode for non-functional BRCA1,
were also detected in some of the BRCA1 mutation cell lines.
BRCA1 regulates FOXA1 expression in human and mouse
mammary epithelial cells
The good correlation between BRCA1 and FOXA1 expression in
the panel of breast cancer cell lines led us to explore further the
possibility that BRCA1 regulates FOXA1 expression. To this end,
BRCA1 was silenced in MCF-7 cells using BRCA1-speciﬁc small
interfering RNA (siRNA) pool. BRCA1 depletion resulted in a
signiﬁcant reduction in FOXA1 expression at both protein
(Figure 2a) and mRNA levels in MCF-7 cells (Figure 2b) when
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Figure 1. BRCA1 correlates with FOXA1 expression in breast cancer
cell panel. (a) Western blot and (b) quantitative reverse
transcription-PCR (qRT–PCR) analysis was performed on a panel of
six different breast cancer cell lines including the luminal-type cell
line MCF-7, which expresses wild-type BRCA1, basal-type cell lines
HCC70, MDA-MB-231, MDA-MB-436, SUM1315MO2 and MDA-
MB-468 expressing either low or mutated BRCA1. The experiments
were repeated three times independently and qRT–PCR results were
normalized against L19 mRNA levels and the results presented as
bars representing mean± s.d.
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compared with the non-silencing control (NSC), supporting the
notion that BRCA1 regulates FOXA1 expression. Conversely, the
knockdown or overexpression of FOXA1 did not affect BRCA1
protein and mRNA levels (Figures 2c and d). Taken together, these
results indicate that BRCA1 regulates FOXA1 expression and not
vice versa, and that BRCA1 regulates FOXA1 expression, at least in
part, at the transcriptional level.
To conﬁrm further that the loss of FOXA1 expression is a result
of BRCA1 depletion in mammary epithelial cells, we next
investigated the effect of re-expressing BRCA1 on FOXA1
expression in Brca1-deﬁcient mouse mammary epithelial cells
(MMECs). Analysis of the expression levels of Foxa1 in Brca1-
deﬁcient KB1P-3.12 (K14cre;Brca1F/F;p53F/F, clone 12) and BRCA1-
reconstituted KB1PR-3.12 E3 and KB1PR-3.12 F4 (K14cre;Brca1F/F;
p53F/F BRCA1-reconstituted clones E3 and F4) MMECs,18 revealed
that Foxa1 expression was signiﬁcantly higher at both the mRNA
and protein levels in the BRCA1-reconstituted cell lines compared
with the parental Brca1-deﬁcient, KB1P-3 12 cells (Figures 3a and
b), further conﬁrming that BRCA1 has a role in modulating FOXA1
expression.
FOXA1 promoter is hypermethylated in the BRCA1-deﬁcient
MMECs compared with the BRCA1-resconstituted cells
DNA methylation is a well-deﬁned epigenetic mechanism for the
repression of gene expression22 and BRCA1 mutation is associated
with speciﬁc global DNA methylation proﬁles in breast cancer.23
These ﬁndings suggested that BRCA1 deﬁciency may lead to DNA
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Figure 2. Knockdown of BRCA1 results in a signiﬁcant decrease in FOXA1 expression and not vice versa in MCF-7 cells. (a) Western blot and (b)
quantitative reverse transcription-PCR (qRT–PCR) analysis was performed MCF-7 cells transfected with BRCA1-speciﬁc siRNA pool for 48 h.
FOXA1 expression was observed to be downregulated both at the protein and mRNA levels. For qRT–PCR analysis, the experiments were
repeated three times independently and the results were normalized against L19 mRNA levels and expressed as mean± s.d. **P⩽ 0.01,
***P⩽ 0.001 and NS, no signiﬁcance by Student's t-test. (c) MCF-7 cells were either non-transfected (Mock) or transfected with NSC siRNA or
with FOXA1 siRNA-speciﬁc pool for 48 h. The protein expression levels of FOXA1, BRCA1 and β-Tubulin were assessed by western blot analysis
(arrows indicate the speciﬁc protein band). Levels of FOXA1, BRCA1 and FOXM1 transcripts were analyzed by qRT–PCR normalized with L19
mRNA levels. (d) MCF-7 cells were transfected with 0, 1, 3 or 6 μg of pcDNA3-FOXA1 or pcDNA3-empty vector for 48 h. Total protein was
extracted from whole-cell lysates were extracted from these cells and analyzed by western blotting with the indicated antibodies (arrow
indicates the speciﬁc protein band). FOXA1 and BRCA1 mRNA levels were also analyzed by qRT–PCR, with results normalized with L19 mRNA
levels. All qRT–PCR results presented as bars representing mean± s.d. of three independent experiments in triplicates. **P⩽ 0.01, ***P⩽ 0.001
and NS indicates no signiﬁcance by Student's t-test.
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methylation and therefore the silencing of FOXA1. To test this
conjecture, we studied the extent of DNA methylation in the CpG
islands located within the Foxa1 gene promoter in the Brca1-
deﬁcient mouse epithelial cells (Figure 3c). In silico analysis using
the UCSC Genome browser website (www.genome.ucsc.edu)
predicted three regions of CpG sites (CpG 50, CpG 74 and CpG
86) within the mouse Foxa1 gene. Bisulphite pyrosequencing
revealed that the Brca1-deﬁcient KB1P-3.12 cells displayed
signiﬁcantly higher levels of DNA methylation at the CpG island
86 that locates nearby the mouse Foxa1 promoter region when
compared with the Brca1-knockout cells reconstituted with BRCA1
(Figure 3d). This suggests that Foxa1 promoter methylation might
contribute to the lower Foxa1 expression observed in the
KB1P-3.12 cells (Figures 3a and b).
Consistently, Foxa1 transcript levels were signiﬁcantly induced
when treating the KB1P-3.12 and KB1PR-3.12 E3 cells with 5-aza-2'-
deoxycytidine (5-aza-dC), a drug that inhibits the activity of DNMT
and suppresses DNA methylation24 (Figure 4), supporting the
notion that Foxa1 promoter is methylated in Brca1-deﬁcient cells.
However, a corresponding induction of FOXA1 at the protein level
was not observed after 5’-aza-dC treatment implicating other
mechanisms exist to regulate FOXA1 post-transcriptionally in
these cells (Supplementary Figure S2).
Knockdown of BRCA1 in MFC-7 induces FOXA1 promoter
methylation
In the human FOXA1 gene, ﬁve CpG islands (CpG 110, CpG 52, CpG
99, CpG 143 and CpG 123) were identiﬁed. We focused on CpG
island 143 as it corresponds to CpG island 86 located at the
promoter region of the mouse Foxa1 gene (Figure 5a). MCF-7 was
transiently transfected with either NSC or BRCA1 siRNA, and
FOXA1 methylation levels analyzed. Methylated and unmethy-
lated DNAs were also used in the pyrosequencing experiment. In
the MCF-7 cells, the FOXA1 promoter was hypomethylated.
Knockdown of BRCA1 led to signiﬁcantly higher levels of
FOXA1 methylation compared with the mock (non-transfected)
and the NSC siRNA-transfected controls (Figure 5b). Western blot
analysis conﬁrmed the knockdown of BRCA1 in MCF-7 cell lines
and FOXA1 expression was reduced by BRCA1 knockdown
(Figure 5c). Collectively, these data suggest that BRCA1 positively
regulates FOXA1 expression, in part, through suppressing
its promoter methylation. However, the relatively low levels
of DNA methylation before and after 5’-aza-dC treatment
suggested that the FOXA1 promoter in the MCF-7 cell line is
undermethylated.
5′-aza-dC treatment induces FOXA1 expression in basal-type cell
lines
To investigate further the relevance of FOXA1 methylation in
repressing FOXA1 expression in basal breast cancer, the basal-type
cell lines SUM1316MO2 and MDA-MB-231 and the luminal-type
cell line MCF-7 were treated with different amounts of 5′-aza-dC
(0, 1 and 5 μM) for 72 h and BRCA1, FOXA1 and EZH2 expression
levels examined by both western blot and quantitative reverse
transcription-PCR. In SUM1315MO2, FOXA1 mRNA expression was
signiﬁcantly induced after treatment with 1 and 5 μM of 5′-aza-dC
treatment (both Po0.05, Student's t-test) (Figure 6a). In agree-
ment, the FOXA1 expression was also induced after being treated
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Figure 3. FOXA1 expression is lower and its promoter more hypermethylated in the BRCA1-deﬁcient murine mammary epithelial cell line.
(a) KB1PR-3.12 E3, KB1PR-3.12 F4 and KB1P-3.12 murine mammary epithelial cell lines were collected and analyzed by western blotting and
(b) quantitative reverse transcription-PCR (qRT–PCR) to determine the expression levels of BRCA1 and FOXA1. qRT–PCR results are presented
as the mean± s.d. of three independent experiments in triplicates. (c) Schematic representation, as presented on UCSC genome web browser,
of the locations of CpG islands in mouse Foxa1 gene and the positions of primers used for pyrosequencing analysis. (d) DNA extracts from
KB1PR-3.12 E3 and KB1P-3.12 cell lines were bisulphite converted and methylation status of Foxa1 promoter region were analyzed by
pyrosequencing. Average Foxa1 methylation values of the two analyzed regions within the CpG island 86, located in the Foxa1 promoter
region, are shown for both cell lines. Results are expressed as the mean± s.d. from two independent experiments in triplicates. *P⩽ 0.05
**P⩽ 0.01, ***P⩽ 0.001 by Student's t-test. TSS, Transcription start site.
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with 5 μM of 5′-aza-dC in MDA-MB-231 cells (Figure 6b). Notably,
the expression of BRCA1 at the mRNA level also increased
signiﬁcantly (Po0.05, Student's t-test) after 5’-aza-dC treatment,
suggesting that DNA methylation contributes to the low BRCA1
expression in this cell line. In fact, promoter methylation has been
reported to be a regulatory mechanism for BRCA1 expression and
is associated with poor prognosis in breast cancer.25,26 On the
contrary, treatment of the luminal MCF-7 with 5’-aza-dC did not
alter the expression levels of FOXA1 (Figure 6c) indicating that, in
the presence of wild-type BRCA1, FOXA1 expression is not
repressed by DNA methylation. Collectively, these results suggest
that DNA methylation has a part in low FOXA1 expression in basal
subtype breast cancers where BRCA1 is either mutated or
depleted (Figure 6d), highlighting a role of BRCA1 in promoting
FOXA1 expression through suppressing FOXA1 methylation in
luminal breast cancers.
Inhibition or depletion of EZH2 induces FOXA1 expression in
BRCA1-deﬁcient mammary epithelial cells
We next explored the mechanism by which BRCA1 regulates
FOXA1 methylation and the cofactors involved. A recent study
showed that BRCA1 interacts with the PRC2 protein EZH2 to
negatively regulate gene expression through promoting histone
H3 lysine 27 trimethylation (H3K27me3) in mouse embryonic stem
and human breast cancer cells.20 These ﬁndings raised the
possibility that BRCA1 modulates FOXA1 methylation and expres-
sion through recruiting EZH2. To test this idea, we treated the
Brca1-deﬁcient KB1P-3.12 murine mammary epithelial cells and
the corresponding BRCA1-reconstituted KB1PR-3.12 E3 cells for
72 h with GSK126, a highly selective, S-adenosyl-methionine-
competitive inhibitor of EZH2 methyltransferase activity27 and
studied its effect on Foxa1 expression. The results showed that
Foxa1 transcript levels were signiﬁcantly induced by treatment
with 5 μM of GSK126 in the BRCA1-deﬁcient KB1P-3.12 cells
(Po0.05, Student's t-test, Figure 7a) but remained largely
constant in the BRCA1-reconstituted KB1PR-3.12 E3 cells
(Figure 7b). This result suggests that EZH2 is involved in the
repression of FOXA1 expression in the BRCA1-deﬁcient cells but
not in the BRCA1-competent cells. However, there were no
changes in FOXA1 protein levels after treatment with GSK126,
indicating that FOXA1 is also regulated at the post-transcriptional
level, consistent with the previous 5’aza-dC treatment results with
these murine cell lines (Supplementary Figure S3). To further
conﬁrm this ﬁnding, we used siRNA to deplete EZH2 in the human
breast cancer MCF-7 cells. The knockdown efﬁciency of EZH2 after
48 h was conﬁrmed by western blot and quantitative reverse
transcription-PCR analysis. It was found that after EZH2 depletion
FOXA1 expression was signiﬁcantly induced both at protein and
mRNA levels when compared with the NSC (Figures 8a and b).
These data corroborate with the hypothesis that EZH2 negatively
regulates FOXA1 transcription in BRCA1-deﬁcient breast
cancer cells.
EZH2 directly interacts with DNMT3b and binds to FOXA1
promoter
Hitherto, our data indicated that BRCA1 inhibits EZH2 activity to
suppress the methylation and silencing of FOXA1. Previously, EZH2
has been shown to cause Histone 3 lysine 27 trimethylation
(H3K27me3) and DNA methylation at target genes by recruiting
DNMTs.16 Collectively, these ﬁndings evoked the idea of EZH2
inducing H3K27 trimethylation and recruiting DNMTs to promote
heterochromatinization and DNA methylation respectively at the
FOXA1 promoter in BRCA1-deﬁcient cells. To test this possibility,
we next investigated by ChIP analysis the in vivo occupancy of the
human FOXA1 promoter region by BRCA1, EZH2, DNMT3b and
H3K27me3 in the BRCA1-positive MCF-7 cells, where the FOXA1
promoter is hypomethylated. Incidentally, the inspection of this
human FOXA1 promoter region also identiﬁed a putative EZH2-
binding motif.28 Primers for ChIP were designed to amplify across
the predicted EZH2-binding region of FOXA1 promoter (Figure 9a).
The ChIP results showed that BRCA1, EZH2, DNMT3b and
H3K27me3 can all bind to the FOXA1 promoter in MCF-7 cells
(Figure 9b). The protein recruitment to the endogenous FOXA1
promoter was also examined by quantitative reverse transcription-
PCR following ChIP (Figure 9c). The results again demonstrated
that BRCA1, EZH2, DNMT3b and H3K27me3 are speciﬁcally
associated with the endogenous FOXA1 promoter region further
supporting our hypothesis that these proteins interact to
modulate FOXA1 methylation and silencing. To further conﬁrm
this, the methylation status of the FOXA1 promoter was examined
in the BRCA1 wild-type and -deﬁcient breast epithelial cell lines
by PCR analysis of bisulﬁte-converted DNA (Supplementary
Figure S4). Surprisingly, the FOXA1 promoter region was
hypomethylated in both BRCA1 wild-type and deﬁcient human
cell lines. Gene promoter hypomethylation has previously been
shown to be due to the prolonged passaging of cell lines and the
immortalization process29 and could explain for the inefﬁcient
derepression of FOXA1 expression in BRCA1-deﬁcient human
breast cancer cell lines after 5’-aza-dC treatment.
BRCA1 represses and EZH2 enhances the deposit of the
H3K27me3 gene silencing histone marker
To investigate further the mechanism involved in FOXA1
repression in BRCA1-deﬁcient cells, we studied the recruitment
of BRCA1, EZH2, DNMT1/3a/3b and H3K27me3 to the endogenous
FOXA1 promoter in MCF-7, MDA-MB-231, SUM131MO2 and
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Figure 4. 5’-Aza-dC treatment induces Foxa1 mRNA expression in
KB1PR-3.12 E3 and KB1P-3.12. The two cell lines were treated with 0,
1 and 5 μM of 5’-aza-dC for 72 h with culture medium changed every
day. Total RNA was extracted and expression of Ezh2 and Foxa1
mRNA was analyzed by quantitative reverse transcription-PCR (qRT–
PCR). The experiments were repeated three times independently
and qRT–PCR results were normalized against L19 mRNA levels and
the results expressed as mean± s.d. *P⩽ 0.05 and **P⩽ 0.001 by
Student's t-test.
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MDA-MB-436 cells by ChIP analysis. Consistent with previous data,
the ChIP results showed that BRCA1, EZH2, DNMT1, DNMT3a and
DNMT3b were all recruited to the FOXA1 promoter albeit at low
levels (all with Po0.05 compared with respective IgG controls;
Figure 10a). Interestingly, high levels of the repressive H3K27me3
histone marks were detected at the FOXA1 promoter in the
BRCA1-deﬁcient MDA-MB-231, SUM131MO2 and MDA-MB-436
compared with the wild-type BRCA1-expressing MCF-7 cells,
suggesting that gene silencing via heterochromatinization could
be the predominant mechanism by which FOXA1 expression is
repressed in the hypomethylated BRCA1-deﬁcient cells. To gain
further information on the spatial relationships between these
proteins in the regulation of FOXA1 repression, we ﬁrst studied the
interactions of BRCA1, EZH2 and DNMT3b in MCF-7 cells by
co-immunoprecipitation. The result showed that both BRCA1 and
DNMT3b co-precipitated with EZH2 but not with each other.
These co-immunoprecipitation data led us to propose that the
BRCA1-containing EZH2 complexes do not contain DNMTs, such
as DNMT3b, and are therefore inactive in DNMT activity. To
validate this, we performed sequential ChIP (ChIP–reChIP) experi-
ments in MCF-7 cells and found that BRCA1 co-occupied the
FOXA1 promoter region with EZH2 but not DNMT1/3a/3b
(Figure 10b). ChIP–reChIP experiments also showed that the levels
of DNMT3b recruited with EZH2 to the FOXA1 promoter were
signiﬁcantly higher in MDA-MB-231 compared with MCF-7 cells
(Supplementary Figure S5). We next examined the role of BRCA1
and EZH2 in the deposit of the histone marker H3K27me3 in
MCF-7 cells by ChIP analysis after BRCA1 or EZH2 silencing.
Interestingly, both the conventional ChIP (Figure 10c) and
qPCR-ChIP (Figure 10d) analysis showed that BRCA1 depletion
enhanced and EZH2 knockdown reduced H3K27me3 levels on the
FOXA1 promoter. This is in agreement with a previous study
showing that BRCA1 binds directly to EZH2 and inhibits PRC2
activity,20 which regulated histone methylation and the DNA
methylation of target genes.16 Consistent with this idea, the
expression of BRCA1 could signiﬁcantly upregulate FOXA1 mRNA
expression in basal-like breast cancer cells, including MDA-MB-231
and MDA-MB-436, but not in the luminal cells, such as MCF-7
(Supplementary Figure S6).
FOXA1 is hypermethylated and downregulated in BRCA1-mutated
tumours
Having established that BRCA1 regulates FOXA1 methylation and
silencing as well as the mechanism involved in human and
MMECs, we next examined the association between FOXA1
methylation and expression in vivo in a published methylated
DNA immunoprecipitation and gene expression microarray data
set derived from familial breast tumour samples collected by
kConFab (The Kathleen Cuningham Foundation Consortium for
Research into Familial Breast Cancer, Melbourne, Australia).23
There are 33 patient samples in the cohort, 11 of which are with
BRCA1 mutation. Statistical analysis of the expression and
methylation proﬁles of FOXA1 in these familial breast cancers
revealed that there was a strong and signiﬁcant inverse correlation
between FOXA1 methylation and expression using both linear
regression model (R2 = 0.127, P= 0.042; Figures 11a and b;
Supplementary Figures S7 and S8) and Pearson’s correlation
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model (cutoff is the mean, Pearson correlation coefﬁcient =
− 0.492, P= 0.004; Figure 11c), providing further physiological
evidence that FOXA1 methylation negatively regulates its expres-
sion in breast cancer patient samples. We also compared the
levels of FOXA1 methylation in different familial breast tumours
and found that FOXA1 methylation levels were signiﬁcantly higher
in BRCA1-mutated tumours compared with BRCA2, BRCAx (non-
BRCA1/2) and BRCA2/x tumours (P= 0.006, P= 0.046 and P= 0.006,
respectively; Student’s t-tests; Figures 10d and e, Supplementary
Figures S9 and S10). Moreover, we also observed that FOXA1
expression was signiﬁcantly lower in BRCA1-mutated tumours
compared with BRCA2, BRCAx and BRCA2/x tumours (Po0.001,
P= 0.001 and Po0.001, respectively; Student's t-test; Figures 11f
and g; Supplementary Figures S11 and S12). These in vivo data
provide further proof that DNA methylation is a major mechanism
for repressing FOXA1 expression in familial breast cancers and
conﬁrm a role for BRCA1 in regulating FOXA1 methylation and
expression.
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DISCUSSION
Mutations to the breast cancer susceptibility gene BRCA1
predispose women to a high lifetime risk of breast and ovarian
cancer.30 BRCA1 is implicated in mammary epithelial cell
differentiation and its deﬁciency associated with basal-like breast
cancer subtype, yet the underlying mechanism involved is still not
well understood. Moreover, although a tumour suppressive role of
BRCA1 in DNA damage repair and cell cycle checkpoint has been
demonstrated, the exact reason whereby BRCA1 deﬁciency causes
predominantly cancers of the breast and ovary also remains
largely unknown. BRCA1 mutation is associated with developing
triple-negative breast cancer of the basal subtype. It is also a
marker for breast cancer endocrine therapy-insensitive and poor
prognosis. Conversely, FOXA1 is a pioneer transcription factor and
a recognized marker for luminal subtype of breast cancer. It is also
a predictor for hormonal responsiveness and good outcome in
breast cancer.10,31
In this study, we show that FOXA1 expression is negatively
regulated by promoter methylation and silencing, and that BRCA1
regulates FOXA1 expression through suppressing its methylation
in both human breast cancer cells and MMECs. FOXA1 expression
is enhanced in basal but not in BRCA1-wild-type MCF-7 cells
following treatment with 5’-aza-dC, supporting our hypothesis
that methylation has a role in FOXA1 silencing in the basal cell
lines. Pyrosequencing further re-enforced that BRCA1-deﬁcent
mouse mammary cell lines are hypermethylated compared with
those expressing wild-type BRCA1, despite the changes in levels of
FOXA1 methylation upon BRCA1 reconstitution are relatively small.
There is evidence to suggest that DNA methylation is gradually
lost passively through many rounds of cell division29 and during
breast epithelial cell immortalization.32 In agreement, bisulphite-
converted PCR analysis showed that the FOXA1 promoter region is
hypomethylated in BRCA1-positive as well as negative human
breast cancer cell lines (Supplementary Figure S4). Nevertheless,
the breast cancer patient gene expression microarray and
methylated DNA immunoprecipitation analyses clearly show that
BRCA1 mutation is signiﬁcantly associated with FOXA1 gene
promoter methylation and expression downregulation.
Interestingly, recent studies have demonstrated that DNA
hypomethylation can cause the redistribution of the H3K27me3
epigenetic marks and derepression of PRC2-targeted genes.33
Conversely, DNA hypomethylation can also be coupled to
repressive chromatin domain formation and gene silencing
through the deposit of H3K27me3 in breast cancer.29 Our data
suggest that FOXA1 gene expression is negatively regulated by
EZH2, a key subunit in PRC2, as chemical inhibition or siRNA-
mediated depletion of EZH2 enhanced FOXA1 expression in
Brca1-knockout MMECs and MCF-7 cells. EZH2 has been shown to
epigenetically suppress target gene expression through modulat-
ing histone methylation, especially H3K27 trimetylation.34,35 In
agreement, our results show that the H3K27me3 repressive
histone mark is highly enriched on the FOXA1 promoter in the
BRCA1-deﬁcient MDA-MB-231, SUM131MO2 and MDA-MB-436
cells compared with the wild-type BRCA1-expressing MCF-7 cells.
Importantly, the ChIP data also demonstrate that BRCA1 depletion
enhances and EZH2 knockdown reduces H3K27me3 levels on the
FOXA1 promoter, further suggesting an antagonistic role of BRCA1
and EZH2 on FOXA1 gene expression. However, in addition to
regulating trimethylation of H3K27, an epigenetic mark for
transcriptionally silent chromatin, EZH2 might also recruit DNMTs,
including DNMT1/3a/3b, to enhance promoter methylation and
gene silencing.36,37 As BRCA1 has been shown to be able to bind
EZH2 and negatively regulate PRC2 complex activity,20 we reason
that BRCA1 can promote the transcription of FOXA1 indirectly
through binding to EZH2 subunit of the PRC2 complex and
restraining its methyltransferase and gene silencing activity. In
agreement, ChIP assays showed that BRCA1, EZH2, DNMT1/3a/3b
and H3K27me3 are recruited to the promoter region of FOXA1.
The low levels of recruitment of DNMT1/3a/3b probably reﬂect the
fact that the FOXA1 gene expression is predominantly repressed
through H3K27me3-associated gene silencing mechanisms rather
than DNA methylation. In addition, co-immunoprecipitation and
ChIP–reChIP experiments also revealed that both BRCA1 and
DNMT3b bind to EZH2 but do not exist in the same complexes,
supporting the notion that BRCA1 binding inhibits the methyl-
transferase activity of EZH2/PRC2. Together these ﬁndings unveil
two epigenetic mechanisms by which BRCA1 and EZH2 combined
to regulate FOXA1 expression in breast epithelial cells, namely
through DNA methylation and H3K27me3-related heterochroma-
tinization (Supplementary Figure S13). Consistent with the ﬁnding
that EZH2 is involved in the epigenetic repression of FOXA1, a
previous genome-wide siRNA screen also revealed FOXA1 as one
of 40 genes derepressed in human embryonic ﬁbroblasts depleted
of PRC2 components, including EZH2, EED and suppressor of zeste
homologue (SUZ12).38 Subsequent ChIP analysis also showed that
SUZ12 is speciﬁcally recruited to the FOXA1 gene, which is
enriched for H3K27me3.38 These ﬁndings are further endorsed by
a number of studies, which also found that FOXA1 expression is
repressed by EZH2.39,40
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Figure 7. EZH2 inhibition by GSK126 treatment induces Foxa1
expression in murine BRCA1-deﬁcient murine mammary epithelial
cell line. The BRCA1-deﬁcient murine mammary epithelial cell line
KB1P-3.12 and the corresponding BRCA1-reconstituted murine cell
line KB1PR-3.12 E3 were treated with 0, 1 or 5 μM of GSK126 for 72 h.
Total RNA was collected and expression of Ezh2 and Foxa1 examined
by quantitative reverse transcription-PCR (qRT–PCR). (a) Foxa1
expression at the mRNA level was signiﬁcantly induced after
treatment with 5 μM of GSK126 in KB1P-3.12 cells. (b) However,
Foxa1 mRNA expression did not show signiﬁcant changes in the
BRCA1-reconstituted murine cell line KB1PR-3.12 E3 after GSK126
treatment. The experiments were repeated three times indepen-
dently and qRT–PCR results normalized against L19 mRNA levels
and the results expressed as mean± s.d. *P⩽ 0.05 and NS indicates
no signiﬁcance by Student's t-test.
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Figure 10. EZH2 but not BRCA1 recruits DNMT3b and H3K27me3 to the FOXA1 promoter. (a) quantitative reverse transcription-PCR (qRT–PCR)
analysis of ChIP showing the recruitment of BRCA1, EZH2, DNMT1, DNMT3a, DNMT3b and H3K27me3 to the endogenous FOXA1 promoter in
MCF-7, MDA-MB-231, MDA-MB-436 and SUM1315MO2 cells. The ChIP results showed that BRCA1, EZH2, DNMT1, DNMT3a and DNMT3b were
all recruited to the FOXA1 promoter albeit at low levels (all with *Po0.05 compared with IgG controls). The fold of enrichment over IgG
(mouse) is shown for ChIP with antibodies against H3K27me3. The experiments were repeated three times independently and the qRT–PCR
results presented as mean± s.d. **P⩽ 0.01 by Student's t-test. (b) BRCA1 and DNMT3b were immunoprecipitated using speciﬁc antibodies and
the precipitated proteins analyzed by western blot analysis. The speciﬁc bands were indicated by arrows. Co-immunoprecipitation (Co-IP)
showed that, in MCF-7 cells, EZH2 associated with BRCA1 and DNMT3b but not in the same complexes. (c) ChIP–reChIP assays were performed
with BRCA1 and EZH2, DNMT1, DNMT3a or DNMT3a antibodies in MCF-7. (d) ChIP analysis was performed on MCF-7 cells after BRCA1 or EZH2
silencing by siRNA and recruitment of BRCA1, EZH2, and H3K27me3 to the endogenous FOXA1 promoter MCF-7 cells were transiently
transfected with smart pool siRNA against BRCA1, EZH2 or control siRNA pool. Twenty-four hours later, the transfected MCF-7 cells were
analyzed for EZH2 and H3K27me3 recruitment to the FOXA1 promoter by ChIP assays. The precipitated chromatin DNA was analyzed by
conventional PCR (e) The precipitated chromatin DNA was quantiﬁed by qRT–PCR. The results were normalized to the amount of Input and
compared with the IgG negative controls. The experiments were repeated three times independently and the qRT–PCR results presented as
mean± s.d. *P⩽ 0.05, **P⩽ 0.01 and ***P⩽ 0.001 by Student's t-test. IgG (r), rabbit IgG negative control. IgG (m), mouse IgG negative control.
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Figure 11. FOXA1 gene promoter is hypermethylated in BRCA1 mutation tumours and its methylation is negatively correlated with its
expression. Frequency of FOXA1 methylation in clinical samples with mutations in BRCA1, BRCA2 and BRCAx tumours was analyzed using the
kConFab database. (a) Signiﬁcant higher percentage of FOXA1 promoter methylation in BRCA1-mutated tumours compared with BRCA2 or
BRCAx mutated tumour. (b and c) FOXA1 expression level inversely correlates with FOXA1 methylation. Box plots represent median (centre
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marker. (d and e) Signiﬁcant higher percentage of FOXA1 promoter methylation in BRCA1-mutated tumours compared with BRCA2 or/and
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FOXA1, ERα and GATA3 are key transcription factors essential
for normal mammary epithelial cell development and
they function cooperatively to regulate the expression of genes
essential for luminal mammary epithelial cell development.13,41,42
FOXA1, ERα and GATA3 co-express in normal breast luminal
epithelial cells and their expression is controlled by complex cross-
regulatory mechanisms. For example, GATA3 regulates the
expression of both ESR1 and FOXA1 mRNA,43–45 ERα regulates
GATA3 mRNA expression,44,45 whereas FOXA1 regulates ESR1 but
not GATA3 expression.9 Moreover, recent genome-wide ChIP-
sequencing studies also show that FOXA1 is involved in the
regulation of ERα-mediated transcription by dictating the binding
location and transcriptional activity of ERα.9 This interdependent
relationship between FOXA1, ERα and GATA3 ensures that a loss
of FOXA1 expression will disrupt the FOXA1–ERα–GATA3 tran-
scriptional network and, therefore, luminal mammary epithelial
cell development. Indeed, FOXA1 expression in breast cancers is
predictive of luminal ERα-positive disease, and co-reexpression of
ERα, FOXA1 and GATA3 has been shown to be able to
reprogramme ER-negative breast cancer cell lines to regain
hormonal sensitivity.41 In addition to promoting mammary
luminal phenotype, FOXA1 might also have a more direct role in
repressing the basal breast cancer phenotype. It has been shown
that FOXA1 also inhibits the transcription of basal-type associated
genes such as CD58, ANXA1, JAG1 and SOX9, whereas the loss of
FOXA1 leads to the derepression of these basal genes.13 These
ﬁndings together highlight a critical role of FOXA1 in maintaining
the luminal and repressing the basal phenotype. In light of these
ﬁndings, collectively, our results lead us to propose a mechanistic
model in which BRCA1 can promote FOXA1 transcriptional
expression and thereby, breast cancer luminal subtype develop-
ment through targeting EZH2 (Supplementary Figure S12).
Conversely, when BRCA1 is silenced or mutated, the activity of
EZH2 is restored, culminating in trimethylation of H3K27,
recruitment of DNMTs to CpG islands, hypermethylation and
silencing of FOXA1 and ultimately, expression of basal genes and
phenotype. In summary, our ﬁndings are of importance for
understanding the aetiology of breast cancer subtypes, with
potential implications for breast cancer diagnosis and therapy.
MATERIALS AND METHODS
Cell culture
The human breast carcinoma cell lines MCF-7, MDA-MB-231, MDA-MB-436,
MDA-MB-468, HCC70 and SUM1315MO2 originated from the American
Type Culture Collection (LGC standards, Middlesex, UK) and were
authenticated by Cancer Research UK (London, UK). The Brca1 knockout
(KB1P-3 12) and reconstituted (KB1P3R E3 and KB1P3R F4) murine breast
epithelial cell lines have been described.18 Also see Supplementary
Materials and methods.
FuGENE6 transfection
Cells were seeded into six-well plates or 100-mm dishes to achieve ~ 60%
conﬂuency before transfection. Plasmid DNA was transfected using
FuGENE 6 (Roche Diagnostics, West Sussex, UK) in a 3:1 ratio (μl of
FuGENE: μg of DNA) following manufacturer’s instructions.
RNA interference with small interfering RNAs (siRNAs)
All siRNAs for the work were ON-TARGETplus SMARTpool siRNA purchased
from Dharmacon Thermo Scientiﬁc (Lafayette, CO, USA). The SMARTpool
siRNAs used in this study were: siBRCA1 (L-003461-00), siEZH2 (L-004218-
00) and the ON-TARGETplus Non-Targeting Pool (D-001810-10). All siRNA
pools were resuspended to 20 μM in 1x siRNA buffer before use.
Statistical analyses
All statistical analyses, unless otherwise speciﬁed, were carried out using
SPSS 16.0 (SPSS Inc., Chicago, IL, USA) and Windows XPs (Microsoft,
Redmond, WA, USA). Where appropriate, a two-tailed independent sample
t-test or a Pearson correlation analysis were performed.
Pyrosequencing and PCR analysis of bisulphite-converted breast
cancer cell line DNA
See Supplementary Materials and methods.
ChIP, real-time quantitative PCR and co-immunoprecipitation
These procedures were performed as previously described.46 See also
Supplementary Materials and methods.
Western blot analysis
Cells were harvested for western blot analysis as described.47 See also
Supplementary Materials and methods.
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